-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nasopharyngeal cancer is a type of cancer that occurs in the nasopharyngeal cavity or upper throat.
in some parts of the world, such as South-East Asia and Africa, more people suffer from the disease than in others, which were thought to be primarily dietary effects and are now tending to be genetically based on major influences.
Chinese pharmaceutical company Junshi Bio recently announced that China's State Drug Administration (NMPA) has accepted a new supplemental drug application for the first-line treatment of relapsed or metastatic nasopharyngeal cancer with Toripalimab combined chemotherapy.
approval is based on the latest results from the JUPITER-02 Study (NCT03581786), a randomized, double-blind, placebo-controlled Phase III study.
results showed that toripalimab monoantigen/cisplatin first-line therapy significantly extended the patient's progressive survival (PFS) when treating patients with relapsed or metastatic nasopharyngeal cancer with monoantigen/cisplatin first-line therapy.
previously, Toripalimab had been awarded the "Breakthrough Therapy Title" and "Orphan Drug Title" from the FDA for the treatment of nasopharyngeal cancer, and Junshi Bio would also submit a Biological Agent Licensing Application (BLA) in the United States.
toripalimab could become the first Chinese anti-PD-1 monoclonal antibody to commercialize in overseas markets.
